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Invasive candidiasis (IC) remains a leading infectious cause of morbidity and 
mortality in severely immunocompromised and/or critically ill patients. Unfavorable 
outcomes of IC could be preventable by early and appropriate implementation of 
antifungal therapy. However, no reliable clinical or molecular indicators are currently 
available for predicting the likely clinical outcome in IC patients at presentation. This 
clinical setting has prompted the search for accurate prognostic biomarkers of IC at an 
early stage with the intention that therapeutic strategies may be tailored accordingly. 
The goal of this study was to identify and validate accurate prognostic features in 
IC patients at presentation by screening of their serum anti-Candida IgG antibody 
profiles. To address this goal, we combined serological proteome analyses with data 
mining procedures. Two-way hierarchical clustering and principal-component analyses 
of reactivity patterns of 31 anti-Candida IgG antibodies segregated IC patients into 
two clusters with distinct prognoses. These subgroups were independent of baseline 
characteristics of the study population. Supervised analysis with cross-validation 
identified a panel of five anti-Candida IgG antibodies as the best prognostic predictor 
for IC. The robustness of this five IgG antibody set was confirmed using an independent 
data set. This panel was able to accurately predicting risk of a fatal outcome in IC 
patients at presentation, and allowed delineation of a high-risk group that may benefit 
from aggressive antifungal therapy. Multivariate logistic-regression analysis revealed 
that this five IgG antibody set was an independent clinical-outcome predictor of IC, 
and further provided additional discriminative power over known prognostic factors 
for IC. We conclude that IC patients could be stratified according to their prognosis 
by examining a reasonably small number of predictor variables (IgG antibodies). If 
our results are confirmed in future larger prospective studies, this new model could be 
useful in predicting patient outcome for individualized therapy of IC.
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